L. Briker
5 Papers
L. Briker is an academic researcher. The author has contributed to research in topics: Neuroblastoma RAS viral oncogene homolog & Melanoma. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Vertical inhibition of the MAPK pathway as potential treatment strategy in NRAS-mutant melanoma
TL;DR: A large proportion of melanomas carry mutations in the mitogen-activated protein kinase (MAPK) signaling pathway leading to hyperactivation and proliferation as mentioned in this paper , and driver mutations in BRAF V600 (50%) and NRAS Q61 (20%) are commonly found.
2
High-Throughput Screening Identifies Novel ROS-Inducing Small Molecules as a Therapy for Treatment-Resistant Melanoma
Corinne Isabelle Stoffel,Ossia M. Eichhoff,Patrick Turko,Phillip Cheng,L. Briker,Andreas Dzung,Reinhard Dummer,Mitchell P. Levesque +7 more
TL;DR: In this paper , the authors employed high-throughput screening of a chemical library of 17,000 small molecules in an NRAS-mutated patient-derived melanoma cell culture derived from a metastatic site to identify ROS-inducing lead compounds that target NRASmutated melanoma cells.
ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma
Ossia M. Eichhoff,Corinne Isabelle Stoffel,Jan Käsler,L. Briker,Patrick Turko,Gergely Karsai,Nina Zila,Verena Paulitschke,Phil F. Cheng,Alexander Leitner,Andrea Bileck,Nicola Zamboni,Anja Irmisch,Zsolt Balázs,Aizhan Tastanova,Susana Pascoal,Pål Johansen,Rebekka Wegmann,Julien Mena,Alaa Othman,Vasanthi S. Viswanathan,Judith Wenzina,A. Aloia,Annalisa Saltari,Andreas Dzung,Michael Krauthammer,Stuart L. Schreiber,Thorsten Hornemann,Martin Distel,Berend Snijder,Reinhard Dummer,Mitchell P. Levesque +31 more
TL;DR: It is shown that metabolic reprogramming sensitizes resistant cells to ROS-induction in combination with pathway inhibitors, highlighting the generalizability of this treatment approach.
ROS induction as a strategy to target persister cancer cell metabolism
Ossia M. Eichhoff,Corinne Isabelle Stoffel,L. Briker,Patrick Turko,Gergely Karsai,Verena Paulitschke,Nicola Zamboni,Z. Balazs,Aizhan Tastanova,Rebekka Wegmann,Julien Mena,Vasanthi S. Viswanathan,C. TuPro,M. Krauthammer,Steffen Schreiber,T. Hornemann,M. Distel,B Snijder,R. Dummer,M. Levesque +19 more
TL;DR: In this article , the authors proposed a kinase inhibitors targeting the mutated BRAF kinase and showed excellent clinical response rates for melanoma with mutations in the NRAS kinase.
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Ossia M. Eichhoff,Corinne Isabelle Stoffel,Jan Käsler,L. Briker,Patrick Turko,Gergely Karsai,Nina Zila,Verena Paulitschke,Phil F. Cheng,Alexander Leitner,Andrea Bileck,Nicola Zamboni,Anja Irmisch,Zsolt Balázs,Aizhan Tastanova,Susana Pascoal,Pål Johansen,Julien Mena,Alaa Othman,Vasanthi S. Viswanathan,Judith Wenzina,A. Aloia,Annalisa Saltari,Andreas Dzung,Rudolf Aebersold,Melike Ak,Faisal S. Al-Quaddoomi,Silvana Iuliana Albert,Jonas B Albinus,Ilaria Alborelli,Sonali Andani,Per-Olof Attinger,Marina Bacac,Daniel Baumhoer,Beatrice Beck-Schimmer,Niko Beerenwinkel,Christian Beisel,Lara Bernasconi,A. Bertolini,Bernd Bodenmiller,Ximena Bonilla,Lars Bosshard,Byron Calgua,Ruben Casanova,Stéphane Chevrier,Natalia Chicherova,Ricardo Coelho,Maya D’Costa,Esther Danenberg,Natalie R. Davidson,Monica-Andreea Dragan,Stefanie Engler,Martin Erkens,Katja Eschbach,Cinzia Esposito,André Fedier,Pedro Ferreira,Joanna Ficek,Anja Frei,Bruno S. Frey,Sandra Goetze,Linda Grob,Gabriele Gut,Detlef Günther,Martina Haberecker,Pirmin Haeuptle,Viola Heinzelmann-Schwarz,Sylvia Herter,René Holtackers,Tamara Huesser,Alexander Immer,Francis Jacob,Andrea Jacobs,Tim Jaeger,Katharina Jahn,Alva Rani James,Philip Jermann,André Kahles,Abdullah Kahraman,Viktor H. Koelzer,Werner Kuebler,Jack Kuipers,Christian P. Kunze,Christian Kurzeder,Kjong-Van Lehmann,Mitchell P. Levesque,Ulrike Lischetti,Sebastian Lugert,Gerd Maass,Markus G. Manz,Philipp Markolin,Martin Mehnert,Julian Metzler,Nicola Miglino,Emanuela S. Milani,Holger Moch,Simone Muenst,Riccardo Murri,Charlotte K.Y. Ng,Stefan Nicolet,Marta Nowak,Mónica Núñez López,Patrick Ga Pedrioli,Lucas Pelkmans,Salvatore Piscuoglio,Michael Prummer,Natalie Rimmer,Mathilde Ritter,Christian Rommel,M. L. Rosano-González,Gunnar Rätsch,Natascha Santacroce,Jacobo Sarabia del Castillo,Ramona Schlenker,Petra C. Schwalie,Severin Schwan,Tobias Schär,Gabriela Senti,Wen-Chuan Shao,Franziska Singer,Sujana Sivapatham,Bettina Sobottka,Vipin T. Sreedharan,Stefan G. Stark,Daniel J. Stekhoven,Tanmay Tanna,Alexandre Theocharides,Tinu Thomas,Markus Tolnay,Vinko Tosevski,Nora C. Toussaint,Mustafa Anil Tuncel,Marina Tusup,Audrey van Drogen,Marcus Vetter,Tatjana Vlajnic,Sandra Weber,Walter P. Weber,Rebekka Wegmann,Michael Weller,Fabian Wendt,Norbert Wey,Andreas Wicki,Mattheus H.E. Wildschut,Bernd Wollscheid,Shuqing Yu,Johanna S Ziegler,Marc Zimmermann,Martin Zoche,Gregor Zuend,Michael Krauthammer,Stuart L. Schreiber,Thorsten Hornemann,Martin Distel,Berend Snijder,Reinhard Dummer +155 more
TL;DR: In this article , the authors used multi-omics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition.